Editas Medicine (EDIT) News Today → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free EDIT Stock Alerts $5.68 -0.03 (-0.53%) (As of 05/14/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 11:16 PM | finance.yahoo.comDirector Jessica Hopfield Acquires 45,000 Shares of Editas Medicine Inc (EDIT)May 14 at 7:19 PM | marketbeat.comInsider Buying: Editas Medicine, Inc. (NASDAQ:EDIT) Director Buys 45,000 Shares of StockEditas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) Director Jessica Hopfield acquired 45,000 shares of the stock in a transaction on Monday, May 13th. The stock was bought at an average price of $5.64 per share, with a total value of $253,800.00. Following the transaction, the director now directly owns 67,700 shares of the company's stock, valued at approximately $381,828. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.May 14 at 10:00 AM | globenewswire.comEditas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in JuneMay 13 at 5:24 AM | americanbankingnews.comEditas Medicine, Inc. (NASDAQ:EDIT) Forecasted to Post Q4 2024 Earnings of ($0.17) Per ShareMay 13 at 4:44 AM | americanbankingnews.comEditas Medicine (NASDAQ:EDIT) PT Lowered to $9.00 at BarclaysMay 13 at 1:38 AM | americanbankingnews.comEditas Medicine (NASDAQ:EDIT) Upgraded to Equal Weight at Morgan StanleyMay 12 at 10:26 AM | finance.yahoo.comEditas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportMay 11 at 1:54 AM | americanbankingnews.comEditas Medicine (NASDAQ:EDIT) Stock Rating Lowered by StockNews.comMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Editas Medicine Amid Promising CRISPR Pipeline and Growth PotentialMay 10, 2024 | markets.businessinsider.comEditas Medicine Hold Rating: Balancing Pipeline Potential with Financial and Legal PrudenceMay 10, 2024 | globenewswire.comEditas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual MeetingMay 9, 2024 | marketbeat.comEditas Medicine (NASDAQ:EDIT) Price Target Cut to $15.00Citigroup reduced their price objective on Editas Medicine from $16.00 to $15.00 and set a "buy" rating for the company in a research report on Thursday.May 9, 2024 | finance.yahoo.comEditas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call TranscriptMay 9, 2024 | marketbeat.comEditas Medicine (NASDAQ:EDIT) Releases Quarterly Earnings Results, Misses Expectations By $0.13 EPSEditas Medicine (NASDAQ:EDIT - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.13). The firm had revenue of $1.10 million during the quarter, compared to the consensus estimate of $11.14 million. Editas Medicine had a negative return on equity of 42.95% and a negative net margin of 196.12%. The firm's revenue for the quarter was down 88.9% compared to the same quarter last year. During the same period last year, the company earned ($0.71) EPS.May 9, 2024 | fool.com1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?May 9, 2024 | markets.businessinsider.comEditas Medicine’s Innovative In Vivo Gene Editing Approach and Positive Clinical Trial Prospects Bolster Buy RatingMay 9, 2024 | markets.businessinsider.comBuy Rating for Editas Medicine: Promising Trials and Solid Financial Footing Propel Growth OutlookMay 9, 2024 | marketbeat.comEditas Medicine (NASDAQ:EDIT) Lifted to Equal Weight at Morgan StanleyMorgan Stanley raised Editas Medicine from an "underweight" rating to an "equal weight" rating and set a $7.00 price target for the company in a report on Thursday.May 9, 2024 | finance.yahoo.comEditas Medicine First Quarter 2024 Earnings: Misses ExpectationsMay 8, 2024 | washingtonpost.comEditas: Q1 Earnings SnapshotMay 8, 2024 | investorplace.comEDIT Stock Earnings: Editas Medicine Misses EPS, Misses Revenue for Q1 2024May 8, 2024 | globenewswire.comEditas Medicine Announces First Quarter 2024 Results and Business UpdatesMay 7, 2024 | msn.comGene Editing Improves Vision in Rare and Devastating Retinal DisorderMay 7, 2024 | msn.comEditas Medicine Q1 2024 Earnings PreviewMay 7, 2024 | markets.businessinsider.comWhat Wall Street expects from Editas Medicine's earningsMay 6, 2024 | msn.comCRISPR gene editing shows promise for treating individuals with a form of inherited blindnessMay 6, 2024 | msn.comClinical trial shows measurable improvement in inherited blindness after gene therapyMay 5, 2024 | finance.yahoo.comEditas Medicine, Inc. (NASDAQ:EDIT) is a favorite amongst institutional investors who own 71%May 3, 2024 | marketbeat.comEditas Medicine (EDIT) to Release Earnings on WednesdayEditas Medicine (NASDAQ:EDIT) will be releasing earnings before the market opens on Wednesday, May 8, Zacks reports.May 2, 2024 | globenewswire.comEditas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor EventsMay 2, 2024 | uk.finance.yahoo.comStocks search for direction ahead of Fed rate decisionMay 1, 2024 | msn.comEditas, Bristol Myers extend T cell therapy collaborationMay 1, 2024 | globenewswire.comEditas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell CollaborationApril 29, 2024 | marketbeat.comEditas Medicine, Inc. (NASDAQ:EDIT) Sees Large Increase in Short InterestEditas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 18,760,000 shares, a growth of 14.7% from the March 31st total of 16,360,000 shares. Based on an average trading volume of 1,910,000 shares, the short-interest ratio is presently 9.8 days.April 26, 2024 | marketbeat.comZacks Research Analysts Boost Earnings Estimates for Editas Medicine, Inc. (NASDAQ:EDIT)Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Investment analysts at Zacks Research increased their Q3 2025 EPS estimates for shares of Editas Medicine in a research note issued on Wednesday, April 24th. Zacks Research analyst A. Chakraborty now anticipates that the company will post earninApril 24, 2024 | investing.comEditas to present gene editing advancements at ASGCTApril 22, 2024 | globenewswire.comEditas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual MeetingApril 20, 2024 | marketbeat.comMirae Asset Global Investments Co. Ltd. Sells 177,556 Shares of Editas Medicine, Inc. (NASDAQ:EDIT)Mirae Asset Global Investments Co. Ltd. lessened its holdings in shares of Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) by 47.3% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 197,971 shares of the company's stock after selling 177,556 shares durinApril 18, 2024 | investing.comEditas Medicine Inc (EDIT)April 15, 2024 | marketbeat.comEditas Medicine (NASDAQ:EDIT) Hits New 52-Week Low at $6.05Editas Medicine (NASDAQ:EDIT) Reaches New 52-Week Low at $6.05April 14, 2024 | marketbeat.comEditas Medicine, Inc. (NASDAQ:EDIT) Short Interest UpdateEditas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) was the recipient of a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 16,360,000 shares, an increase of 17.4% from the March 15th total of 13,930,000 shares. Based on an average trading volume of 1,840,000 shares, the short-interest ratio is presently 8.9 days.April 10, 2024 | marketbeat.comInternational Assets Investment Management LLC Grows Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT)International Assets Investment Management LLC increased its position in shares of Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) by 1,183.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 288,269 shares of the company's stock after buApril 9, 2024 | finance.yahoo.comDr. Chi Li Joins Curevo Vaccine as Chief Regulatory OfficerApril 8, 2024 | marketbeat.comVanguard Group Inc. Has $66.58 Million Stock Position in Editas Medicine, Inc. (NASDAQ:EDIT)Vanguard Group Inc. grew its stake in shares of Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) by 4.5% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,536,208 shares of the company's stock after purchasing an additioMarch 22, 2024 | marketbeat.comEditas Medicine, Inc. Forecasted to Earn Q1 2024 Earnings of ($0.85) Per Share (NASDAQ:EDIT)Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Equities researchers at Zacks Research cut their Q1 2024 earnings estimates for Editas Medicine in a report released on Wednesday, March 20th. Zacks Research analyst A. Chakraborty now expects that the company will earn ($0.85) per share for theMarch 21, 2024 | marketbeat.comEditas Medicine, Inc. Forecasted to Earn FY2026 Earnings of ($2.80) Per Share (NASDAQ:EDIT)Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Analysts at Zacks Research issued their FY2026 earnings per share (EPS) estimates for Editas Medicine in a research report issued on Wednesday, March 20th. Zacks Research analyst A. Chakraborty forecasts that the company will earn ($2.80) per shMarch 18, 2024 | marketbeat.comShort Interest in Editas Medicine, Inc. (NASDAQ:EDIT) Increases By 7.4%Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) was the target of a large increase in short interest in the month of February. As of February 29th, there was short interest totalling 13,520,000 shares, an increase of 7.4% from the February 14th total of 12,590,000 shares. Based on an average daily volume of 1,940,000 shares, the days-to-cover ratio is presently 7.0 days.March 13, 2024 | seekingalpha.comEditas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)March 12, 2024 | seekingalpha.comEditas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript)March 7, 2024 | fool.com1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right. Get Editas Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Email Address Did Intel Just Dethrone Nvidia? (Ad)Intel (INTC) just announced a brand-new AI venture - the Aurora supercomputer. This computer was specifically designed for artificial intelligence and is now the fastest AI-centered computer on the planet. You can get all the details here. EDIT Media Mentions By Week EDIT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EDIT News Sentiment▼0.040.56▲Average Medical News Sentiment EDIT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EDIT Articles This Week▼314▲EDIT Articles Average Week Get Editas Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: C4 Therapeutics News Today Taysha Gene Therapies News Today Adaptive Biotechnologies News Today Voyager Therapeutics News Today iTeos Therapeutics News Today Lexeo Therapeutics News Today Fate Therapeutics News Today Allogene Therapeutics News Today Alvotech News Today Alector News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EDIT) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsCharles Payne Demystifies OptionsUnstoppable ProsperityRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressElon to Transform U.S. Economy? Porter & CompanyThe only AI company you should be looking atBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
